Eton Pharmaceuticals (NASDAQ:ETON) Earns Buy Rating from HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $33.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 123.27% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. B. Riley started coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective for the company. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Eton Pharmaceuticals Trading Down 0.7 %

ETON stock opened at $14.78 on Wednesday. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $18.41. The company has a fifty day simple moving average of $15.56 and a 200 day simple moving average of $11.47. The firm has a market cap of $385.03 million, a PE ratio of -67.18 and a beta of 1.37.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million. As a group, analysts forecast that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ETON. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the period. Wasatch Advisors LP bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth about $1,431,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth about $54,000. Parkman Healthcare Partners LLC increased its holdings in shares of Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after purchasing an additional 7,029 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth about $90,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.